News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Large spread. Really haven't been looking.
.008 / .0475
Had a run up to .094?
.005 looks cheap
|
Followers
|
11
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
139
|
|
Created
|
11/19/14
|
Type
|
Free
|
| Moderators | |||
Electroceuticals: Microcurrents as medicine
Bioelectric medicine was born 60 years ago with the pacemaker. Using electro-technologies to modify bodily functions grew slowly and steadily after that … from pacemakers in 1958, to spinal cord stimulation (SCS) in 1967, to inner ear implants in 1978… bioelectric medicine has come a long way towards extending the lives of patients.
Discoveries like those were so sporadic and treated so many different symptoms that most people didn’t realize they were connected… yet they’re all bioelectronics, also called electro-medicine.
With advances in micro processing this field is suddenly exploding, and yesterday’s slow-and-seldom breakthroughs have turned into a tsunami of rapid discoveries and new treatments. These new treatments are so much more flexible and powerful that they’ve caught the attention of a number of major corporations who are developing electroceutical devices of their own.
This Technology Just Spawned a New Medical Sector with a Fast Growing $35 Billion Market
Grandview Research predicts that electroceutical/bioelectric medicine will be a $35.5 billion market by 2025. Many forward-thinking investors have already taken positions in bioelectric medicine, as the field is still young and has enormous growth potential. Another sign that bioelectric medicine is on firm footing is the number of major corporations that are entering the sector, below are examples of 4 corporations making strides in bioelectric medicine.
GlaxoSmithKline (GSK), with support from Alphabet, set up Galvani Bioelectronics to work on an implant device that will wrap around a bundle of nerves to treat diseases.
Boston Scientific (BSX) & Medtronic (MDX) – Both companies have a long history in bioelectronics with pacemakers and spinal cord stimulation devices.
Nevro Corp. (NVRO) – Makes pain control devices using spinal cord stimulation (SCS).
The common theme with the above examples is that their procedures are all invasive in nature. Standing out amongst these large corporations is a small company by the name of Cell MedX who has just completed observational clinical trials for their eBalance device.
Cell MedX Corp. (CMXC) – Is a pure-play electroceutical that has just completed observational clinical trials for its eBalance device.
Unique Opportunity in a Pure Electroceuticals Play
The very nature of Cell MedX’s eBalance device is very different from other microcurrent systems. Instead of stimulating the spinal cord or muscles or providing other localized application of electrical stimulation, eBalance instead delivers microcurrents in various strengths, frequencies and waveforms through the body in 15 to 30 minute treatments.
Observational Clinical Trial Results as Reported by the Company
An observational clinical trial was completed on diabetic subjects using 3 months of eBalance treatments twice weekly (the “Trial”) with no significant side effects or safety issues. The following results were observed during the Trial;
Diabetes
After three months of bi-weekly eBalance treatments, the average fasting blood glucose levels declined by 12.3% and plasma insulin declined by 46.7%. These results indicate that, on average, the blood glucose uptake was increased and that less insulin was required to achieve that uptake. A longer double-blind, placebo controlled study may be conducted in the future to determine if grater effects are achieved as seen in individuals who have used the device over extended periods of time.
Blood pressure
After 7 weeks of treatments, systolic pressure, the higher amount of pressure in the arteries during the contraction of the heart muscle, declined by 9.6% and diastolic pressure, the lower pressure number in the arteries when the heart muscle is between beats, declined by 10.4%. The Company is planning to undertake further studies on subjects with higher blood pressures to determine if a proportional effect is obtained as has been observed with in individuals who have used the eBalanceTM device. A 10% decrease in blood pressure for individuals at risk from high blood pressure could be very beneficial without the side effects of medications.
Pain and numbness
Neuropathy is nerve damage that can occur with diabetes as a result of high blood glucose levels and high blood pressure. The damage most often affects the extremities and causes pain, tingling or numbness in the hands, arms, legs and feet. Only two subjects suffered from pain at the beginning of the Trial and both reported feeling either less pain or reduced coldness or numbness in their extremities. These findings support our individual findings and he Company is wanting to conduct further studies on neuropathy and other forms of chronic pain, such as gout, migraines and inflammation.
Kidney function
Nephropathy is damage caused to the small blood vessels in the kidneys by high blood glucose levels and high blood pressure that prevents them from functioning properly or even causes them to fail completely. When the blood vessels in the kidneys are injured, the kidneys cannot clean the blood properly. The body will retain more water and salt than it should, which can result in weight gain and edema. In the Trial, there were some indications that eBalance treatments improved kidney function which is supported by individual observations of significant reductions of edema. A longer study on studies on kidney function is highly desirable.
Cell MedX Corp. (CMXC), a fully-reporting US-listed company and a reporting issuer in Canada
Investing in Cell MedX (CMXC)
Unique Electroceutical Opportunity—CellMedX offers a pure play on the fast-evolving field of electroceuticals.
Millions of Potential Users—Having completed observational trials to demonstrate the efficacy for diabetes, blood sugar and blood pressure treatment, CellMedX is targeting the
global population of 380 million diabetics and 1.1 Billion people suffering from high blood pressure.
Meaningful Innovation—The eBalance device may prove to be an important breakthrough in diabetes management.
Outstanding safety—Even insulin therapy can be dangerous for diabetics, but the eBalance microcurrent treatments through its observational clinical trials has demonstrated no harmful side effects.
Easy to use— eBalance incorporates a user-friendly interface.
Pipeline Potential —Outstanding potential for follow-on devices built with the same technology to address other health problems.
Global Ambition— Cell MedX (CMXC) is taking the necessary steps to gain approval in the US, EU, and Commonwealth countries.
https://www.grandviewresearch.com/press-release/global-electroceuticals-bioelectric-medicine-market
Continue reading about the eBalance Solution
Forward Looking Statements
The information included in this press release has not been reviewed by the FDA, nor has it been peer reviewed. This press release contains forward-looking statements. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as “expects”, “intends”, “estimates”, “projects”, “anticipates”, “believes”, “could”, and other similar words. All statements addressing product performance, events, or developments that the Company expects or anticipates will occur in the future are forward-looking statements. Because the statements are forward-looking, they should be evaluated in light of important risk factors and uncertainties, some of which are described in the Company’s Quarterly, Annual and Current Reports filed with the United States Securities and Exchange Commission (the “SEC”). Should one or more of these risks or uncertainties materialize, or should any of the Company’s underlying assumptions prove incorrect, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on Company’s forward-looking statements. In particular, the Company’s eBalance technology is still in development. Except as required by law, Cell MedX Corp. disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. No stock exchange, securities commission or other regulatory body has reviewed nor accepts responsibility for the adequacy or accuracy of this release. Investors are advised to carefully review the reports and documents that Cell MedX Corp. files from time to time with the SEC, including its Annual, Quarterly and Current Reports.
As we begin this new millennium, we rely on various forms of technology to diagnose our patients through an ever increasing list of new diseases. New therapeutic technologies for a variety of disorders also offer a remarkable and unprecedented track record both in safety and efficacy.
The application of electromagnetic forces to human tissues to effect change has been around since the 19th century. A good deal of that was wishful thinking or deliberate deception. But what has survived, and is now seeing resurgence in legitimate, peer-reviewed biologic research, is the concept of molecular bioelectricity and its role in cell-to-cell signaling. Ion flows and trans-membrane gradients produced by ion channels and pumps are key regulators of cell proliferation, migration, and differentiation. Now, instructive roles for bioelectrical gradients in embryogenesis, regeneration, and neoplasm are being revealed. There is speculation of “cracking the bioelectric code” with the same excitement that portended the cracking of the genetic code.
Also helpful in the discovery pathway is the fact that diabetics have been benefiting from micro-current delivery devices since 1987. Treatment of diabetic neuropathy using programmed delivery of electrical currents is well known, as is the use of microcurrents for non-healing wounds. The e-balance Technology is different. Based on first-in-human observations carefully documented by the discoverers of this technology, a specific device with a specific set of bioelectric signals of known waveform, frequency, amplitude, pulse, and duration, accompanied by sensing circuits that respond to fluctuations in the body’s response, in a closed feedback loop, effect global improvements in Type 1 diabetes.
Conventional medical treatments do not take advantage of the potent ways that energy can transmit information in biological systems. Healthy and unhealthy tissues have distinct electromagnetic properties that can be detected in scanned images. Lipton observes that “diseased tissue emits its own unique energy signature emitted by surrounding healthy cells”. He goes on to suggest that there is enough scientific evidence to tailor energy and waveforms that act as therapeutic agents in much the same way that we now modulate chemical structures with drugs.
Cell MedX products employ energy in nature and are designed to provide an enhanced treatment result to conventional therapies in the management of pain and chronic disease conditions. The high-tech advancements of the 21st century can now provide a new quality of life and lifestyle.
Our products are a breakthrough approach to support a new age of predictive, personalized wellness treatments grounded in each person’s personal profile. The power of direct-to-consumer wellness with the potential to manage diseases/issues we have inherited, and what can be forestalled by specific lifestyle treatments is the 21st century model.
Carson City, Nevada, June 28, 2019, Cell MedX Corp. (OTCQB: CMXC, 9CX:MUN) (“Cell MedX” or the “Company”), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, is pleased to announce that on June 24, 2019, the Company closed the first tranche of its non-brokered private placement … Continued
Carson City, Nevada, June 21, 2019, Cell MedX Corp. (OTCQB: CMXC, 9CX:MUN) (“Cell MedX” or the “Company”), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, announced today that it has retained Think Ink Marketing Data & Email Services, Inc. (“Think Ink”) to develop an investor … Continued
Carson City, Nevada, May 30, 2019, Cell MedX Corp. (OTCQB: CMXC, 9CX:MUN) (“Cell MedX” or the “Company”), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, has arranged a non-brokered private placement offering (the “Offering”) set at a price of $0.12 per Unit for up to … Continued
Carson City, Nevada, March 27, 2019, Cell MedX Corp. (OTCQB: CMXC, 9CX:MUN) (“Cell MedX” or the “Company”), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, announced today that on March 21, 2019, the Company entered into a definitive agreement for exclusive worldwide distribution rights of … Continued
Carson City, Nevada, February 12, 2019, Cell MedX Corp. (OTCQB: CMXC, 9CX:MUN) (“Cell MedX” or the “Company”), an early development stage biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness is pleased to announce significant progress toward obtaining premarket clearance in the US for its eBalance device. … Continued
Carson City, Nevada, December 31, 2018, Cell MedX Corp. (OTCQB: CMXC, 9CX:MUN) (“Cell MedX” or the “Company”), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, announces that on December 27, 2018, the Company entered into an Agreement with Mr. Richard Jeffs (the … Continued
Carson City, Nevada, December 12, 2018, Cell MedX Corp. (OTCQB: CMXC, 9CX:MUN) (“Cell MedX” or the “Company”), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness is pleased to announce that it has successfully completed its first 100 Canadian manufactured eBalance devices. Upon … Continued
Carson City, Nevada, December 4, 2018, Cell MedX Corp. (OTCQB: CMXC, 9CX:MUN), (“Cell MedX” or the “Company”), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, announced today that the Company received electrical and safety certification for the Company’s eBalance Pro device (the … Continued
Carson City, Nevada, September 14, 2018, Cell MedX Corp. (OTCQB: CMXC, 9CX:MUN), (“Cell MedX” or the “Company”), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, announced today that on September 10, 2018, the Company entered into a non-binding letter of intent (the “LOI”) with … Continued
Carson City, Nevada, May 7, 2018, Cell MedX Corp. (OTCQB: CMXC, 9CX:MUN), (“Cell MedX” or the “Company”), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, announced today that, effective April 30, 2018, Dr. Terrance Owen resigned from his management and directorship
AI
